Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1

Reproductive Sciences

Volumn 23, Issue 4, 2016, Pages 542-548

  Nugent, William H ^a   Mishra, Nikita ^a,b   Strauss, Jerome F ^a   Walsh, Scott W ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

hypertension; matrix metalloproteinase 1; preeclampsia; protease activated receptor 1; vasoconstriction

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; INTERSTITIAL COLLAGENASE; PROTEINASE ACTIVATED RECEPTOR 1; RHO KINASE; N3-CYCLOPROPYL-7-((4-(1-METHYLETHYL)PHENYL)METHYL)-7H-PYRROLO(3, 2-F)QUINAZOLINE-1,3-DIAMINE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; DOSE RESPONSE; ENDOTHELIUM; FEMALE; HUMAN; HUMAN TISSUE; PREECLAMPSIA; PRIORITY JOURNAL; VASOCONSTRICTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; OMENTUM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; PREGNANCY; VASCULARIZATION; YOUNG ADULT;

ADULT; ANGIOTENSIN II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 1; OMENTUM; ORGAN CULTURE TECHNIQUES; PRE-ECLAMPSIA; PREGNANCY; PYRROLES; QUINAZOLINES; RECEPTOR, PAR-1; VASOCONSTRICTION; YOUNG ADULT;

EID: 84961241128     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719115607998     Document Type: Article

References (54)

1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L,. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013; 170 (1): 1-7.
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R,. Pre-eclampsia. Lancet. 2010; 376 (9741): 631-644.
3. Huppertz B, Weiss G, Moser G,. Trophoblast invasion and oxygenation of the placenta: measurements versus presumptions. J Reprod Immunol. 2014; 101-102: 74-79.
4. Hubel CA,. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999; 222 (3): 222-235.
5. Walsh SW,. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol. 1998; 16 (1): 93-104.
6. Walsh SW, Vaughan JE, Wang Y, Roberts LJ II,. Placental isoprostane is significantly increased in preeclampsia. FASEB J. 2000; 14 (10): 1289-1296.
7. Clark P, Boswell F, Greer IA,. The neutrophil and preeclampsia. Semin Reprod Endocrinol. 1998; 16 (1): 57-64.
8. Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol. 2001; 185 (4): 792-797.
9. Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA,. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989; 96 (8): 978-982.
10. Sacks GP, Studena K, Sargent K, Redman CW,. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998; 179 (1): 80-86.
11. Leik CE, Walsh SW,. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004; 44 (1): 72-77.
12. Cadden KA, Walsh SW,. Neutrophils, but not lymphocytes or monocytes, infiltrate maternal systemic vasculature in women with preeclampsia. Hypertens Pregnancy. 2008; 27 (4): 396-405.
13. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK,. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161 (5): 1200-1204.
14. Taylor RN, de Groot CJ, Cho YK, Lim KH,. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998; 16 (1): 17-31.
15. Shah TJ, Walsh SW,. Activation of NF-kappaB and expression of COX-2 in association with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J Obstet Gynecol. 2007; 196 (1):48. e1-e8.
16. Pei D,. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell. 2005; 7 (3): 207-208.
17. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A,. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005; 120 (3): 303-313.
18. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C,. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des. 2003; 9 (28): 2349-2365.
19. Trivedi V, Boire A, Tchernychev B, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009; 137 (2): 332-343.
20. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW,. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 1993; 296 (pt 3): 803-809.
21. Grab DJ, Nyarko E, Barat NC, Nikolskaia OV, Dumler JS,. Anaplasma phagocytophilum-Borrelia burgdorferi coinfection enhances chemokine, cytokine, and matrix metalloprotease expression by human brain microvascular endothelial cells. Clin Vaccine Immunol. 2007; 14 (11): 1420-1424.
22. Zhu Y, Hojo Y, Ikeda U, Takahashi M, Shimada K,. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J Cardiovasc Pharmacol. 2000; 36 (2): 152-161.
23. Nagase H, Visse R, Murphy G,. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69 (3): 562-573.
24. Nagase H, Suzuki K, Enghild JJ, Salvesen G,. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim Acta. 1991; 50 (4-6): 749-754.
25. Estrada-Gutierrez G, Cappello RE, Mishra N, et al. Increased expression of matrix metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of vascular dysfunction. Am J Pathol. 2011; 178 (1): 451-460.
26. Coughlin SR,. Protease-activated receptors in vascular biology. Thromb Haemost. 2001; 86 (1): 298-307.
27. Eto M, Barandier C, Rathgeb L, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001; 89 (7): 583-590.
28. Schini VB, Vanhoutte PM,. Endothelin-1: a potent vasoactive peptide. Pharmacol Toxicol. 1991; 69 (5): 303-309.
29. Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL,. G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J Biol Chem. 1995; 270 (42): 24631-24634.
30. Coughlin SR,. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005; 3 (8): 1800-1814.
31. Mishra N, Nugent WH, Mahavadi S, Walsh SW,. Mechanisms of enhanced vascular reactivity in preeclampsia. Hypertension. 2011; 58 (5): 867-873.
32. Cao X, Luo T, Luo X, Tang Z,. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens Res. 2014; 37 (9): 803-810.
33. Abramovich DR, Page KR, Wright F,. Effect of angiotensin II and 5-hydroxytryptamine on the vessels of the human foetal cotyledon. Br J Pharmacol. 1983; 79 (1): 53-56.
34. Maigaard S, Forman A, Andersson KE,. Differential effects of angiotensin, vasopressin and oxytocin on various smooth muscle tissues within the human uteroplacental unit. Acta Physiol Scand. 1986; 128 (1): 23-31.
35. Mak KK, Gude NM, Walters WA, Boura AL,. Effects of vasoactive autacoids on the human umbilical-fetal placental vasculature. Br J Obstet Gynaecol. 1984; 91 (2): 99-106.
36. Tulenko TN,. The actions of prostaglandins and cyclo-oxygenase inhibition on the resistance vessels supplying the human fetal placenta. Prostaglandins. 1981; 21 (6): 1033-1043.
37. Aalkjaer C, Danielsen H, Johannesen P, Pedersen EB, Rasmussen A, Mulvany MJ,. Abnormal vascular function and morphology in pre-eclampsia: a study of isolated resistance vessels. Clin Sci (Lond). 1985; 69 (4): 477-482.
38. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST,. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001; 20 (2): 185-194.
39. Fernandez-Patron C, Radomski MW, Davidge ST,. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999; 85 (10): 906-911.
40. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST,. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013; 61 (2): 488-493.
41. Goerge T, Barg A, Schnaeker EM, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006; 66 (15): 7766-7774.
42. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993; 91 (4): 1269-1281.
43. van Mourik JA, Romani de Wit T, Voorberg J,. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol. 2002; 117 (2): 113-122.
44. Marsen TA, Simonson MS, Dunn MJ,. Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. Circ Res. 1995; 76 (6): 987-995.
45. Greer IA, Leask R, Hodson BA, Dawes J, Kilpatrick DC, Liston WA,. Endothelin, elastase, and endothelial dysfunction in pre-eclampsia. Lancet. 1991; 337 (8740): 558.
46. Taylor RN, Varma M, Teng NN, Roberts JM,. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 1990; 71 (6): 1675-1677.
47. Mousa AA, Cappello RE, Estrada-Gutierrez G, et al. Preeclampsia is associated with alterations in DNA methylation of genes involved in collagen metabolism. Am J Pathol. 2012; 181 (4): 1455-1463.
48. Shukla J, Walsh SW,. Neutrophil release of myeloperoxidase in systemic vasculature of obese women may put them at risk for preeclampsia. Reprod Sci. 2015; 22 (3): 300-307.
49. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC,. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973; 52 (11): 2682-2689.
50. Poole RM, Elkinson S,. Vorapaxar: first global approval. Drugs. 2014; 74 (10): 1153-1163.
51. Lohn M, Plettenburg O, Kannt A, et al. End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899. World J Cardiol. 2015; 7 (1): 31-42.
52. Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013; 77 (10): 2619-2625.
53. Lee YH, Song GG,. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J Intern Med. 2013; 28 (6): 701-707.
54. Hu J, Van den Steen PE, Sang QX, Opdenakker G,. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6 (6): 480-498.